NeuroSense Therapeutics shares positive results of lead candidate in ALS
The neurodegenerative disease currently affects more than 200,000 people worldwide
Read More
Tag: NeuroSense Therapeutics
- Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis
- Lebrikizumab shows strong results for children with atopic dermatitis
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
